Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain autoimmune conditions. Ultomiris is given as an intravenous (IV) infusion by a healthcare professional. The drug’s dosing ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular atrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results